CPIXNasdaqPharmaceutical PreparationsFiscal year ends December 31
CUMBERLAND PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.70−0.48 (-6.69%)
Close on Oct 19, 2026
- Market cap
- $100.38M
- P/E (TTM)
- –
- Dividend yield
- –
CUMBERLAND PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $40.40M | $36.54M | $37.51M | $40.68M | $35.05M | $35.84M | $32.41M | $28.80M | $40.38M | $32.48M | 90.7% | +10.6% |
| Sancuso | $11.91M | $9.01M | $8.10M | $13.21M | – | – | – | – | – | – | 26.7% | +32.2% |
| Kristalose | $10.54M | $15.32M | $15.98M | $15.21M | – | – | – | – | – | – | 23.7% | -31.2% |
| Vibativ | $9.48M | $7.16M | $8.81M | $7.49M | $11.70M | $10.87M | $8.69M | $5.08M | $0 | $0 | 21.3% | +32.5% |
| Caldolor | $4.66M | $4.96M | $4.33M | $4.83M | – | – | – | – | – | – | 10.5% | -6.0% |
| Other | $4.13M | $1.33M | $2.04M | $1.33M | $939.78K | $1.60M | $1.98M | $540.93K | $773.57K | $547.38K | 9.3% | +210.1% |
| Other revenue | $4.13M | $1.33M | – | – | – | – | – | – | – | – | 9.3% | +210.1% |
| Talicia | $3.31M | $0 | – | – | – | – | – | – | – | – | 7.4% | – |
| Acetadote | $508.17K | $185.18K | $458.76K | $501.04K | – | – | – | – | – | – | 1.1% | +174.4% |
| RediTrex | $11.39K | $90.24K | -$341.89K | -$126.73K | – | – | – | – | – | – | 0.0% | -87.4% |
| Vaprisol | -$10.44K | -$3.08K | $20.03K | $29.15K | – | – | – | – | – | – | -0.0% | +239.4% |
| Omeclamox-Pak | -$18.35K | -$174.54K | $151.34K | -$447.70K | – | – | – | – | – | – | -0.0% | -89.5% |
| Acetadote | – | – | – | $501.04K | $850.99K | $1.87M | $3.82M | $4.28M | $6.58M | $7.21M | – | – |
| Caldolor | – | – | – | $4.83M | $4.97M | $5.34M | $5.22M | $5.00M | $4.18M | $4.13M | – | – |
| Kristalose | – | – | – | $15.21M | $15.99M | $15.57M | $12.90M | $12.06M | $11.46M | $15.90M | – | – |
| Product, Acetadote, Generic | – | – | – | – | – | – | – | $3.10M | $4.60M | $4.80M | – | – |
| Omeclamox-Pak | – | – | – | – | -$388.66K | $257.09K | $837.83K | $623.30K | $1.80M | $2.54M | – | – |
| Vaprisol | – | – | – | -$447.70K | $1.86M | $1.08M | $936.62K | $1.76M | $1.58M | $1.86M | – | – |
| Ethyol | – | – | – | – | – | – | $12.77M | $10.55M | $10.84M | $838.39K | – | – |
| Totect | – | – | – | – | – | – | $369.91K | $850.97K | $3.99M | $0 | – | – |
| Redi Trex | – | – | – | -$126.73K | $55.32K | $856.66K | – | – | – | – | – | – |
| Sancuso | – | – | – | $13.21M | $0 | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Cumberland Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.